Welcome to our dedicated page for CYABRA SEC filings (Ticker: CYAB), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on CYABRA's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into CYABRA's regulatory disclosures and financial reporting.
Cyabra, Inc. entered into securities purchase agreements for a private placement of common stock, pre-funded warrants and Series A and Series B common warrants, with expected gross proceeds of approximately $6.0 million at a combined price of $0.435 per share and accompanying warrants. The securities are being issued in reliance on exemptions under Section 4(a)(2) and Rule 506(b) of Regulation D, and Cyabra plans to use the net proceeds for working capital and other general corporate purposes.
The company agreed to file a registration statement to cover the resale of the shares and warrant shares and accepted issuance and variable-rate financing restrictions tied to the date stockholder approval is obtained. Cyabra also entered into agreements to reduce the conversion price of its Series A and Series B convertible preferred stock to $0.435 per share and convert all such preferred shares into common stock (or pre-funded warrants), and to exchange Series C convertible preferred stock with an aggregate value of $10,660,000 for securities on the same economic terms as the private placement, with these capital structure changes subject to stockholder approval.
Cyabra, Inc. (CYAB) filed a prospectus supplement attaching its Form 10-Q for the quarter ended March 31, 2026, reporting a net loss of $10,770 (USD thousands) and accumulated deficit of $58,143 as of that date. The company completed a business combination on March 27, 2026, converted legacy instruments into equity and received PIPE proceeds of $8,000 (USD thousands).
The balance sheet shows $3,122 cash and cash equivalents and shares outstanding of 14,064,191 as of May 14, 2026. Management discloses substantial doubt about going concern and notes Nasdaq notified the company it was below the $50 million MVLS threshold, with a cure period to November 9, 2026.
Cyabra, Inc. furnished an investor presentation via a current report, outlining its disinformation-security platform, business model, and recent performance metrics. The deck shows revenues of $1,922K, $4,155K, and $5,707K for 2023, 2024, and 2025, implying about 72% CAGR, with gross margins rising from 69% to 85%.
The presentation highlights a projected disinformation-security market of over $30B in annual spend by 2028, a SaaS and API-based subscription model, and customer case studies in social media, consumer brands, and information warfare. It also notes industry recognition and an experienced leadership team and board.
Cyabra, Inc. has received two deficiency notices from Nasdaq, signaling that its stock no longer meets key continued listing standards. Nasdaq found that Cyabra’s Market Value of Publicly Held Shares was below $15,000,000 for 30 consecutive business days ended June 8, 2026, and its common stock traded below the minimum bid price of $1.00 per share for the same period.
The stock remains listed on Nasdaq under the symbol CYAB while the company has until December 7, 2026 to cure both issues, including achieving the required levels for at least ten consecutive business days. If Cyabra fails to regain compliance, its shares could be delisted, although the company may appeal or seek transfer to Nasdaq’s Capital Market. Cyabra states it is working diligently and monitoring its share price, but it cautions there is no assurance it will regain compliance.
CYABRA, INC. Chief Financial Officer Yael Sandler received an equity grant tied to company stock. On May 14, 2026, Sandler was awarded 40,000 restricted stock units under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan, vesting over three years through April 1, 2029. Each RSU converts into one share of common stock, giving Sandler 40,000 shares of direct ownership reported after this compensation-related award.
Flanagan James Francis reported acquisition or exercise transactions in this Form 4 filing.
CYABRA, INC. director James Francis Flanagan received an equity award in the form of restricted stock units. On May 14, 2026, he was granted 110,000 RSUs under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan, with each RSU representing one share of common stock.
The RSUs vest over three years through April 1, 2029, meaning the shares will be delivered gradually as service conditions are met. After this grant, Flanagan’s reported direct holdings from this award total 110,000 shares of common stock-equivalent.
Shraga Ido reported acquisition or exercise transactions in this Form 4 filing.
CYABRA, INC. reported that Chief Technology Officer Shraga Ido received an equity compensation grant of 130,000 restricted stock units (RSUs) of common stock on May 14, 2026 under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan. The RSUs vest in quarterly installments of 26,000 shares of common stock through July 1, 2027, with each RSU representing one share. Following this grant, Ido holds 840,549 shares of common stock directly. The award was granted at a stated price of $0.0000 per share, reflecting a non-cash compensation grant rather than an open-market purchase.
CYABRA, INC. Chief Product Officer Yossef Daar received a grant of 130,000 restricted stock units of common stock as equity compensation. The grant was made at no cash cost per share and increases his directly held position to 840,549 common shares.
The RSUs were issued under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan and vest in quarterly installments of 26,000 shares of common stock through July 1, 2027. Each RSU converts into one share of common stock as it vests, aligning part of the executive’s compensation with future company performance.
Heymann Emmanuel reported acquisition or exercise transactions in this Form 4 filing.
CYABRA, INC. reported that Chief Revenue Officer Emmanuel Heymann received an equity award in the form of restricted stock units. On May 14, 2026, he was granted 100,000 RSUs under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan, each representing one share of common stock. The RSUs vest over three years through April 1, 2029, aligning a portion of his compensation with the company’s longer-term performance and share price.
Madon Michael P reported acquisition or exercise transactions in this Form 4 filing.
Cyabra, Inc. director Michael P. Madon received an equity grant of 100,000 restricted stock units. The RSUs were awarded on May 14, 2026 under the Cyabra, Inc. 2026 Omnibus Equity Incentive Plan and carry a grant price of $0.00 per share.
The award vests over three years through April 1, 2029, with each RSU representing the right to receive one share of common stock. Following this grant, Madon holds 100,000 shares or RSUs directly, reflecting compensation rather than an open-market purchase or sale.